Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate in obese type 2 diabetic patients
NCT00231530Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of topiramate in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Johnson & Johnson. Primary endpoints: Percent change in body weight at Week 60 and Change in Hemoglobin A1c at Week 60. Started Jan 2001; status: completed.
02
Drugs
topiramate
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00231530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231530.